Switch theme
Sign up to access all valuation multiples
Medy-Tox Inc. is a Korea-based company engaged in the development, manufacture, and marketing of biopharmaceuticals. The company's main product is type-A botulium toxin biopharmaceuticals which are used as remedies for blepharospasms, hemifacial spasms, eye wrinkles, hyperhidrosis diseases and infantile cerebral palsy. The group provides its products under the brand names of Neuronox, Siax and others. It distributes its products within Korean and to overseas markets, such as Japan, China, Russia and Europe, among others.
2000
n/a
LTM Revenue $164M
LTM EBITDA $33.7M
$753M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Medy-Tox has a last 12-month revenue of $164M and a last 12-month EBITDA of $33.7M.
In the most recent fiscal year, Medy-Tox achieved revenue of $156M and an EBITDA of $26.7M.
Medy-Tox expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Medy-Tox valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $151M | $156M | XXX | XXX | XXX |
| Gross Profit | $86.1M | $91.2M | XXX | XXX | XXX |
| Gross Margin | 57% | 59% | XXX | XXX | XXX |
| EBITDA | $22.9M | $26.7M | XXX | XXX | XXX |
| EBITDA Margin | 15% | 17% | XXX | XXX | XXX |
| Net Profit | $25.2M | $6.6M | XXX | XXX | XXX |
| Net Margin | 17% | 4% | XXX | XXX | XXX |
| Net Debt | $67.7M | $32.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 25, 2025, Medy-Tox's stock price is KRW 164600 (or $112).
Medy-Tox has current market cap of KRW 1.08T (or $738M), and EV of KRW 1.11T (or $753M).
See Medy-Tox trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $753M | $738M | XXX | XXX | XXX | XXX | $2.34 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 25, 2025, Medy-Tox has market cap of $738M and EV of $753M.
Medy-Tox's trades at 4.6x LTM EV/Revenue multiple, and 22.3x LTM EBITDA.
Analysts estimate Medy-Tox's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Medy-Tox and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $753M | XXX | XXX | XXX |
| EV/Revenue | 4.8x | XXX | XXX | XXX |
| EV/EBITDA | 28.2x | XXX | XXX | XXX |
| P/E | 63.9x | XXX | XXX | XXX |
| P/E/Growth | 0.8x | XXX | XXX | XXX |
| EV/FCF | 62.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMedy-Tox's NTM/LTM revenue growth is 15%
Medy-Tox's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Medy-Tox's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Medy-Tox's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Medy-Tox and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 33% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 23% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 52% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medy-Tox acquired XXX companies to date.
Last acquisition by Medy-Tox was XXXXXXXX, XXXXX XXXXX XXXXXX . Medy-Tox acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Medy-Tox founded? | Medy-Tox was founded in 2000. |
| Where is Medy-Tox headquartered? | Medy-Tox is headquartered in South Korea. |
| Who is the CEO of Medy-Tox? | Medy-Tox's CEO is Mr. Hyeon-Ho Jeong. |
| Is Medy-Tox publicy listed? | Yes, Medy-Tox is a public company listed on KRX. |
| What is the stock symbol of Medy-Tox? | Medy-Tox trades under 086900 ticker. |
| When did Medy-Tox go public? | Medy-Tox went public in 2009. |
| Who are competitors of Medy-Tox? | Similar companies to Medy-Tox include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Medy-Tox? | Medy-Tox's current market cap is $738M |
| What is the current revenue of Medy-Tox? | Medy-Tox's last 12-month revenue is $164M. |
| What is the current EBITDA of Medy-Tox? | Medy-Tox's last 12-month EBITDA is $33.7M. |
| What is the current EV/Revenue multiple of Medy-Tox? | Current revenue multiple of Medy-Tox is 4.6x. |
| What is the current EV/EBITDA multiple of Medy-Tox? | Current EBITDA multiple of Medy-Tox is 22.3x. |
| What is the current revenue growth of Medy-Tox? | Medy-Tox revenue growth between 2023 and 2024 was 3%. |
| Is Medy-Tox profitable? | Yes, Medy-Tox is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
